Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Sharib Ali specialises in the applications of AI to early oesophageal cancer detection

Headshot of oxford cancer researcher Sharib Ali

Barrett’s Oesophagus is a medical condition when the cells lining the lower part of your oesophagus become damaged, which is believed to be caused by acid and bile repeatedly coming up from your stomach. It is a precancerous condition, with Barrett’s Oesophagus patients at 20-30% increased risk of getting oesophageal cancer (although only one in 860 people with Barrett’s go on to develop cancer each year).

Currently, endoscopy is the widely accepted tool for diagnosis and staging of any gastrointestinal related abnormalities, including the identification of Barrett’s Oesophagus. However, the ability to accurately detect those who are at risk (or at the early stages of) developing cancer is highly operator dependent, leaving much room for human error. As a result, many cancers are not detected as early as they could (and when they are more easily treated). Also, as the vast majority of Barrett’s Oesophagus patients never develop cancer, significant resource is wasted in unproductive screening. There is therefore a strong need to reduce this margin of error and improve the quality of endoscopic surveillance.

Dr. Sharib Ali from the Department of Engineering is working on building AI-based technologies for early oesophageal cancer detection and risk quantification. He believes that by introducing AI-based technologies that have learnt from expert knowledge, we can reduce this margin of error. This project has been ongoing since 2017, the first stage of which was focused on overcoming some of the issues related to using endoscopic videos to train AI. Sharib says, “working with endoscopy videos to build any robust methods is often challenging due to inconsistent lighting, hand motion and other debris floating.”

A year ago the team proposed very comprehensive methods using a fully automatic framework to tackle this (which you can read more about here). Since then, Sharib has built AI detection and segmentation methods to better diagnose cancer and cancer like precursors (such as Barretts oesophagus) from endoscopic videos.

He says: “Building AI technologies is getting more common in every stream of science, however, to build a technology that can generalise and adapt to changes such as patient tissue variability or simply choice of modality is a real challenge.”

He adds another challenge is to collaborate with multiple centres with a common goal and be able to deliver something that will actually transform the early oesophageal cancer diagnosis.

To date, Sharib has initiated a collaboration between 6 different institutions world-wide and this number continues to grow. The major outcome of this work is the collection and curation of multi-modality, multi-institutional and multi-population endoscopy videos and frames, which have since been made publicly available for researchers and AI enthusiasts to tackle such concrete and open problems.

As part of this ongoing project, Sharib has organised two upcoming data science challenges and workshops at the 16th and the 17th IEEE International Symposium in Biomedical Imaging which attracts over 500 researchers across the globe. He says, “due to global pandemic, this year we successfully conducted a virtual workshop via zoom and we had over 90 attendees for this. Our data science challenge is attracting more researchers and we had nearly 40% increased number from last years’.”

Sharib Ali who is located at Big Data Institute and works at Rittscher’s lab (Prof. Jens Rittscher) at the Department  Engineering, Oxford, is working closely with clinical endoscopists (Dr. Adam Bailey, Prof. Simon Leedham, Prof. Barbara Braden and Dr. James East) at the TGU and molecular biologists from the Ludwig Institute for Cancer Research, Oxford Branch (including Prof. Xin Lu). Sharib’s research is funded by the NIHR Oxford Biomedical Research Center.

Similar Stories

First patient dosed with lung cancer immunotherapy vaccine

The first patient has been dosed in the MAGE trial, which is testing a novel immunotherapeutic known as VTP-600, in patients with the most common type of lung cancer.

Eileen Parkes awarded Wellcome Clinical Research Career Development Fellowship

Eileen will investigate the expression of genetic instability and how it shapes the immune microenvironment of oesophageal cancers.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.